alvac-cea-b7.1 vaccine
Vaccineexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 1997 (NCT00004032)
Timeline
Indications
Mechanism of action
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, active
CEACAM5 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- alvac-cea-b7.1 vaccine
- alvac-hb7.1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00027833 | Phase 2 | Dec 1, 2001 | Herbert Irving Comprehensive Cancer Center, National Cancer Institute (NCI) |
| NCT00003556 | Phase 1 | Jan 1, 1999 | National Cancer Institute (NCI), University of Alabama, Birmingham |
| NCT00004032 | Phase 1 | Oct 1, 1997 | National Cancer Institute (NCI), University of Texas at Houston |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 2 | 2 | 1997 |
| Herbert Irving Comprehensive Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2001 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 1999 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 1997 |
4 organizations
Page 1 / 1